PsO background & importance
PsO is not just a skin condition
Systemic nature
- Chronic, immune‑mediated, inflammatory condition
- Affects more than the skin—linked to multiple organ systems
- Red, scaly plaques on elbows, knees, scalp, and lower back
Prevalence in the U.S.
Approximately 7.9 million US adults had PsO in 2023 (3% of the total population)
- ~1.7M insured patients have moderate to severe PsO, possibly higher prevalence in uninsured
- Often undiagnosed, particularly in people of color
- Up to 59% may be untreated
Plaque PsO most common form (80–90%)
- Typical locations: elbows, knees, scalp, lower back
- Other forms: guttate, inverse, pustular, erythrodermic
PsO is associated with other immune-related comorbidities. Early diagnosis and intervention can improve outcomes
Common comorbidities include:
Psoriatic arthritis
Cardiovascular disease
Metabolic syndrome
Inflammatory bowel disease
Liver disease
Kidney disease
Mood disorders
Who is at risk for PsO?
Age
Most common onset: 20s–30s and 50s–60s.
Family history
Risk rises—28% with one affected parent, 65% when both parents have PsO.
Immune‑mediated conditions
Higher risk in individuals with inflammatory bowel disease, rheumatoid arthritis, and other inflammatory diseases.
Skin types
Affects all skin types; though presentation may vary—often underdiagnosed in people of color.
Other risk factors/triggers
Obesity, smoking, alcohol use, infections (eg, strep), skin trauma, and emotional stress may trigger or worsen PsO.
Importance of early diagnosis and treatment
Goal = Initiate treatment early to relieve symptoms, limit systemic inflammation, and prevent related complications.
Comorbidity risk
Delayed diagnosis increases risk of metabolic syndrome, depression, diabetes, cardiovascular disease, lymphoma, and non‑melanoma skin cancer.
Cardiovascular risk
PsO linked to higher rates of myocardial infarction, stroke, thromboembolism, and arrhythmias; risk rises with PsO severity.
Comorbid autoimmune disease risk
Strong epidemiologic association with Crohn’s disease and ulcerative colitis.
Musculoskeletal involvement prevention
~30% may develop psoriatic arthritis; PsO may also manifest in axial diseases like ankylosing spondylitis.
Why do delays in PsO care occur?
Misdiagnosis or late diagnosis
PsO is sometimes mistaken for eczema or other skin conditions, delaying proper treatment.
Lack of access to specialists
Limited availability of dermatologists, especially in rural or underserved areas.
Underestimation of severity
Patients may view symptoms as minor or cosmetic, unaware of systemic risks.
Cost and insurance barriers
High cost of advanced therapies (eg, biologics); inadequate insurance coverage causes delays.
Treatment fatigue
Time‑consuming regimens and long‑term medications may lead to poor adherence.
Comorbidities and complexity
Coexisting conditions (eg, cardiovascular disease, arthritis) can delay treatment due to care coordination challenges.
Stigma and mental health
Shame, embarrassment, or anxiety may prevent patients from seeking or continuing care.
What happens if PsO is not treated?
Higher risk of complications including psoriatic arthritis and diabetes.
Persistent symptoms can impact daily activities, social interactions, and emotional functioning.
Severe PsO may impact lifespan by 4‑6 years.